Newsroom

May 2019

• 
  Story May 28, 2019 Discovery

  Investigating the myopia mystery

  Two scientists from Basel are trying to shed light on why myopia is impacting more and more people.

• Ad hoc release May 24, 2019

  FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

  Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone…
• Ad hoc release May 24, 2019

  AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

  One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA   Annualized cost of Zolgensma is USD…
• Ad hoc release May 24, 2019

  AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

  SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1],[2…
• 
  Story May 24, 2019 Discovery

  Cancer research drives breast cancer treatment forward

  Novartis team perseveres to develop more personalized approach to breast cancer therapy.

• Press release May 23, 2019

  Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

  Driving growth through cutting edge pipeline with 15 in-market blockbusters and more than 25 potential blockbusters in development, including 10+ planned launches by 2021  Strong progress on…
• Press release May 22, 2019

  Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment

  New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled…
• 
  Story May 17, 2019 Discovery

  Respiratory clinical trials: Putting patients at the heart of research

  All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.

• Press release May 16, 2019

  Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

  Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO   Primary…
• Featured News May 15, 2019

  SOLAR-1 NEJM Publication

• Press release May 10, 2019

  Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS

  Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya® (fingolimod) 0.5mg had significantly fewer relapses than patients…
• 
  Story May 09, 2019 Discovery

  Women in Science: Sandrine Piret-Gérard

  Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.